The world over, members of the Reproductive Health Supplies Coalition work tirelessly to broaden access to a range of affordable, quality contraceptives. In March, we will gather in Brussels to share our successes and, in particular, to celebrate the advances towards supply security in francophone Africa. This region boasts some of the world’s greatest reproductive health successes but also some of the most troubling statistics and seemingly intractable challenges.
As a new member of this coalition, Avivia is committed to making a valuable contribution.
February 20, 2018
From big pharma, through the smaller biotechnology companies all the way to university research teams and spin outs. The DDF Summit brings the most interesting studies and exciting technologies to you.
Avivia will participate at this event, so if you would like to meet us there, please get in touch!
February 20, 2018
Professor Dr. P.H. Nibbering from the Department of Infectious Diseases - UMC Leiden (LUMC) has received an NWO grant entitled: Next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP).
The project focuses on the development of a synthetic peptide for topical wound treatment, in response to growing concern for untreatable infections, due to antimicrobial resistance.
Together with LUMC and other project partners involved, Avivia will perform several parallel development tests, using nanoparticles and PLGA microspheres, to optimize the delivery of SAAP-148 deep into wounds with a controlled release over time.
December 19, 2017
London dec 2017
In the past 10 years, Avivia has been involved in the pharmaceutical application of mesoporous silica in a diverse range of functionalities in pharmaceutical formulations, ranging from its "simple" application as a processing aid, to the more advanced applications in solubility, stability and bioavailability improvement and most recently the construction of stable ternary amorphous systems.
December 19, 2017
The APGI (Association de Pharmacie Galénique Industrielle) is organizing for the first time a workshop dedicated to Oral Controlled Release Solid Dosage forms. This includes matrix systems as well as coated dosage forms, such as tablets, pellets and capsules.
During the one day event, oral and poster presentations from academia and industry as well as practical demonstrations (in small groups) are foreseen.
The entire spectrum, ranging from engineering aspects during the manufacturing process, the portfolio of commercially available excipients allowing to formulate a large variety of drugs, the underlying mass transport mechanisms and physical principles, characterization methods for the key properties of the devices as well as potential pitfalls and hurdles to be overcome during product development will be addressed.
July 5, 2017
There are many aspects to developing medication for orphan indications. But how and when do you take the all-decisive steps that lead to success?
Come and join us during a 2-day bootcamp in Leuven, Belgium, where you will find answers to your questions, and an update on breaking innovations in orphan diseases from frontline speakers.
May 24, 2017
Are you a (post)doctoral researcher thinking about your next career move?
How about combining Industrial and Academic research?
We currently have development projects in oncology, women´s health and gastrointestinal diseases.
May 16, 2017
Avivia launches a new service division - fully dedicated to pharmaceutical excipient characterization
Excipients can have an important impact on the performance of a pharmaceutical formulation, including its stability, bioavailability and release profile. It’s therefore critical to have a complete and detailed characterization of all the excipients used in a finished dosage formulation in order to achieve a robust, stable and reproducible product.
Excipia has built a unique set of databases and complementary methods covering more than 400 pharmaceutical excipients.
March 2, 2017
The collaboration will combine EmulTech’s innovative technology with Avivia’s expertise in complex drug reformulation to deliver solutions for today’s increasing request from pharmaceutical companies. Both companies encounter customers with complex product ideas who are hitting a wall. Whether it being a new product or reformulation product, life cycle management or generics plus. Teaming up with EmulTech was a natural step as Avivia was looking to strengthen its offering to its customer and EmulTech was looking to do the same.
January 31, 2017
Avivia headquarters & lab facilities
M-building – Novio Tech Campus
6534 AT Nijmegen, The Netherlands
Phone +31 (0)6 1968 6732